Sandoz Tells FDA Unique Biosimilar Names OK… Sometimes
Executive Summary
If biosimilar sponsor doesn’t want brand name, nonproprietary name should have suffix, Sandoz says in update to its citizen petition.
You may also be interested in...
FDA Claims Sole Authority Over Naming Of US-Licensed Biologics
Deferring to nonproprietary names established by US Pharmacopeia without exercising independent judgment ‘would be untenable,’ FDA says in citizen petition response to industry; agency offers statutory defense of decision to require distinguishable suffixes for all novel biologics and biosimilars.
FDA Claims Sole Authority Over Naming Of US-Licensed Biologics
Deferring to nonproprietary names established by US Pharmacopeia without exercising independent judgment ‘would be untenable,’ FDA says in citizen petition response to industry; agency offers statutory defense of decision to require distinguishable suffixes for all novel biologics and biosimilars.
Biosimilar Suffix Detractors Hope Private Studies Build Their Case
Consortium’s biosimilar pharmacovigilance could provide data foundation to pressure FDA that suffixes are not needed in non-proprietary names.